There are seven distinct types of psoriasis, and treatment varies significantly between them. Plaque psoriasis responds well to topical coal tar and corticosteroids. Scalp psoriasis needs formulations that penetrate through hair. Inverse psoriasis — which appears in skin folds — requires lower-potency treatments because the skin in those areas is thinner and absorbs medication at higher rates. Pustular psoriasis is treated very differently from plaque. Erythrodermic psoriasis is a medical emergency requiring immediate systemic care.

Many patients assume they have plaque psoriasis when they actually have another type, or have overlapping presentations. Knowing the specific type isn't just academic — it directly determines which treatments are appropriate and which could make things worse.¹

Dermatologists classify psoriasis severity using measures like body surface area (BSA) affected, the Psoriasis Area and Severity Index (PASI), and quality of life impact. Mild is generally under 3% BSA; moderate is 3–10%; severe is above 10% or wherever the condition significantly affects quality of life, regardless of surface area covered.

Severity determines the treatment tier. OTC treatments are appropriate for mild disease. Phototherapy and systemic medications enter the picture for moderate disease. Biologics are reserved for moderate-to-severe cases, particularly when other treatments have failed. Understanding where you fall helps you understand why certain treatments are or aren't being recommended — and gives you a baseline to track improvement against.¹

Dermatologists often start with what's most likely to work — which is efficient, but means patients sometimes don't know what alternatives exist if the first option fails or causes side effects. Ask for the full picture: what are all the options appropriate for your severity and type, and what are the tradeoffs between them?

This is especially important because some treatments have lifestyle implications — methotrexate requires alcohol avoidance, certain biologics require injections, phototherapy requires 2–3 visits per week for months. Knowing the full range of options lets you participate in choosing based on what's realistic for your life, not just what's clinically appropriate in the abstract.²

Unrealistic expectations are one of the most common reasons patients abandon treatments that would have eventually worked. Topical steroids may reduce itch within a week but take 4–8 weeks for plaque clearance. Coal tar and salicylic acid work cumulatively — results build gradually over 4–8 weeks of consistent nightly use, not overnight. Biologics may take 12–16 weeks to reach full effect.

Ask specifically: what does partial response look like, what does full response look like, and at what point should you consider the treatment a failure and move to something else? Having a defined timeline prevents premature abandonment and also prevents continuing something that genuinely isn't working.¹

Psoriasis is a lifelong condition, which means most effective treatments will be used for years or decades — not just weeks. The risk profile of a treatment used for six weeks is very different from the same treatment used continuously for three years.

Topical corticosteroids used long-term can cause skin thinning, discoloration, and rebound flares when stopped. Methotrexate requires regular liver monitoring. Cyclosporine is generally limited to short courses due to kidney and blood pressure effects. Biologics have long-term safety data that continues to accumulate. Ask your dermatologist what monitoring is required with your prescribed treatment, how often you'll need bloodwork or check-ins, and what the plan is if side effects develop.¹

Up to 30% of people with psoriasis develop psoriatic arthritis — but many go undiagnosed for years because joint symptoms are attributed to other causes, or because the skin and joint conditions aren't connected in the patient's mind. Psoriatic arthritis causes pain, stiffness, and swelling in joints, most commonly in the fingers, toes, lower back, and knees. It can occur before, after, or at the same time as skin symptoms.

Early diagnosis matters because psoriatic arthritis causes progressive joint damage that isn't reversible. If you have any joint symptoms, flag them explicitly — don't assume your dermatologist will ask. Some patients need a rheumatologist referral in addition to dermatology care.³

Treatment resistance is common in psoriasis. The immune system can neutralize biologics over time. Skin can develop tolerance to topical steroids (tachyphylaxis). Disease progression can outpace what a given treatment tier can manage. Knowing the contingency plan before you need it reduces the disruption when it happens.

Ask what the next step is if your current treatment loses effectiveness — a dose adjustment, a different drug in the same class, a step up to the next treatment tier, or a combination approach. This question also signals to your dermatologist that you understand treatment is a process, not a single decision, and that you're engaged in managing it over time.¹

This question often doesn't get asked, and the answer matters more than most patients realize. Alcohol consumption reduces biologic effectiveness and is contraindicated with methotrexate. Smoking is associated with more severe disease and poorer treatment response. Obesity reduces biologic response — adipose tissue produces inflammatory cytokines that work against the medication. Chronic stress drives flares through well-documented immune pathways.

Ask your dermatologist specifically which lifestyle factors are most relevant for your situation — not for a generic wellness lecture, but because some of these have measurable clinical impact on whether your treatment works. The AAD explicitly includes lifestyle modification as part of psoriasis treatment guidelines.⁴

Many patients end up in a cycle of using topical corticosteroids continuously because they're not aware that non-steroidal alternatives exist for maintenance. Coal tar and salicylic acid — the two oldest and most validated OTC psoriasis treatments — have no tolerance development and no skin-thinning risk, making them suitable for sustained daily use. Vitamin D analogues (calcipotriene) are steroid-free prescription topicals. Newer non-steroidal options like tapinarof and roflumilast cream have been approved and are increasingly available.

The standard approach recommended by the AAD is to use topical steroids for active flares and rotate to non-steroidal treatments for maintenance — keeping steroids available as an acute tool rather than a daily baseline. If your current routine is steroid-only, this question opens the conversation about a more sustainable long-term plan.¹

Progress in psoriasis treatment can be gradual enough that it's hard to assess without a baseline. Ask your dermatologist what they're measuring — PASI score, BSA percentage, quality of life assessment — and what a meaningful response looks like in those terms. If you're tracking yourself at home, photos taken at the same location under consistent lighting are the most reliable method.

Also establish clear return criteria: when should you schedule a follow-up regardless of how things are going, and what symptoms should prompt you to come in sooner? Knowing the monitoring plan keeps you from waiting too long when something changes — or coming in unnecessarily when normal variation is occurring.²